Keratinocyte growth factor impairs human thymic recovery from lymphopenia

The lymphocyte-depleting antibody alemtuzumab is a highly effective treatment of relapsing-remitting multiple sclerosis (RRMS); however 50% of patients develop novel autoimmunity post-treatment. Most at risk are individuals who reconstitute their T-cell pool by proliferating residual cells, rather t...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	JCI insight Ročník 4; číslo 12
Hlavní autoři:	Coles, Alasdair J., Azzopardi, Laura, Kousin-Ezewu, Onajite, Mullay, Harpreet Kaur, Thompson, Sara A.J., Jarvis, Lorna, Davies, Jessica, Howlett, Sarah, Rainbow, Daniel, Babar, Judith, Sadler, Timothy J., Brown, J. William L., Needham, Edward, May, Karen, Georgieva, Zoya G., Handel, Adam E., Maio, Stefano, Deadman, Mary, Rota, Ioanna, Holländer, Georg, Dawson, Sarah, Jayne, David, Seggewiss-Bernhardt, Ruth, Douek, Daniel C., Isaacs, John D., Jones, Joanne L.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States American Society for Clinical Investigation 20.06.2019
Témata:	Adolescent Adult Animals CD4-Positive T-Lymphocytes - immunology CD52 Antigen - metabolism Clinical Medicine Disease Models, Animal Female Fibroblast Growth Factor 7 - pharmacology Fibroblast Growth Factor 7 - therapeutic use Humans Lymphopenia - drug therapy Male Mice Middle Aged Multiple Sclerosis, Relapsing-Remitting - immunology Young Adult T cell development Immunology Autoimmune diseases T cells Therapeutics
ISSN:	2379-3708, 2379-3708
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!